12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Deals

Ascletis, Roche deal

Roche granted Ascletis exclusive, Chinese rights to the pharma's HCV compound danoprevir. Under the deal, Ascletis will fund development, regulatory...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >